CV Sciences Q3 2022 revenue down 27% YoY to $3.8M, operating loss narrowed to $0.9M

CV Sciences, Inc.

2022-Q3 EPS reported -$0.05 revenue$12,336,000

Revenue $3.8M, down 27% from $5.1M; gross margin 41.6% vs 46.2%.
Operating loss improved to $0.9M from $3.0M; negative adjusted EBITDA $1.2M vs $2.7M.
Cash balance $1.1M; extinguished entire outstanding convertible debt.
Preliminary approval of settlement of six shareholder derivative lawsuits; continues strategic review including M&A.
Launched PlusCBD Reserve Collection; maintains #1 hemp extract brand in natural channel per SPINS.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CV Sciences, Inc. reported the quarter ended September 30, 2022 results: revenue $3.8 million.

Period: the quarter ended September 30, 2022
Revenue: $3.8 million
Result: reported results

Exact text from the filing

today announced its financial results for the quarter ended September 30, 2022. Third Quarter 2022 and Recent Financial and Operating Highlights • Revenue of $3.8 million for third quarter of 2022

View on SEC.gov

Browse all earnings releases →

CV Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001510964-22-000085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.